Medroxyprogesterone

Medroxyprogesterone: Drug Information

Medroxyprogesterone: Drug Information

Navigation
1. Drug Name
2. Pharmacological Class
3. Mechanism of Action
4. Indications
5. Dosage and Administration
6. Pharmacokinetics
7. Contraindications
8. Warnings and Precautions
9. Side Effects
10. Drug Interactions
11. Pregnancy and Lactation
12. Patient Counseling Information

1. Drug Name

Generic Name

Medroxyprogesterone

Brand Name(s)

  • Pakistan: Provera
  • India: Deviry
  • US: Provera, Depo-Provera
  • UK: Provera, Depo-Provera

2. Pharmacological Class

Class

Progestin

Subclass

Derivative of progesterone

3. Mechanism of Action

Medroxyprogesterone is a progestin hormone that primarily acts by inhibiting the secretion of gonadotropins (LH and FSH) by the pituitary gland. This prevents follicular maturation and ovulation.

4. Indications

Primary Indications

  • Menstrual disorders: Treatment of abnormal uterine bleeding due to hormonal imbalance.
  • Contraception: Prevention of pregnancy with the use of Depo-Provera injection.

Off-label Uses

  • Endometrial hyperplasia
  • Metastatic uterine or renal carcinoma

5. Dosage and Administration

Standard Dosage

For oral tablets (Provera):

  • Menstrual disorders: 5-10 mg daily for 5-10 days starting on the 16th or 21st day of the menstrual cycle.
  • Endometrial hyperplasia: 5-10 mg daily for 12-14 days per month, usually given in combination with estrogen replacement therapy.

For injectable suspension (Depo-Provera):

  • Contraception: 150 mg intramuscularly every 3 months.

Route of Administration

Oral (tablets), Intramuscular (injection)

Special Populations

  • Pediatric: Safety and efficacy not established in children.
  • Geriatric: Use with caution, as elderly patients may be more susceptible to adverse effects.

6. Pharmacokinetics

Absorption

Well-absorbed after oral administration.

Distribution

Bioavailability is high. Protein binding is approximately 90%.

Metabolism

Metabolized extensively in the liver.

Excretion

Excreted in the urine.

Half-life

Elimination half-life is approximately 25-50 hours.

7. Contraindications

  • Pregnancy (Category X)
  • Undiagnosed vaginal bleeding
  • History of thrombosis or thromboembolic disorders
  • Known or suspected breast cancer

8. Warnings and Precautions

  • Increased risk of thromboembolic disorders
  • Increased risk of breast cancer
  • Monitor for signs of depression

9. Side Effects

Common Side Effects

  • Irregular vaginal bleeding
  • Headache
  • Weight changes

Serious Side Effects

  • Thromboembolic disorders
  • Breast cancer
  • Depression

10. Drug Interactions

Major Interactions

  • Warfarin
  • Phenytoin

Moderate Interactions

  • Rifampin
  • Carbamazepine

Minor Interactions

  • Ascorbic acid (Vitamin C)
  • Acetaminophen

11. Pregnancy and Lactation

Pregnancy Category

Category X - Contraindicated during pregnancy.

Breastfeeding Considerations

Not recommended during breastfeeding. Small amounts of medroxyprogesterone may pass into breast milk.

12. Patient Counseling Information

  • Follow the prescribed dosing schedule carefully.
  • Report any unusual bleeding or symptoms immediately.
  • Discuss contraceptive options and potential side effects with your healthcare provider.

Post a Comment

Previous Post Next Post